Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors

Author： Krause Mechthild   Gurtner Kristin   Deuse Yvonne   Baumann Michael  

Publisher： Informa Healthcare

ISSN： 1362-3095

Source： International Journal of Radiation Biology, Vol.85, Iss.11, 2009-11, pp. : 943-954

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 1, Iss. 2, 2006-06 ,pp. : 209-222

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical development of EGFR-tyrosine kinase inhibitors in Japan

By Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 1, 2006-11 ,pp. : 33-37

Springer Publishing Company

Access to resources Recommend Favorite

Clinical development of EGFR-tyrosine kinase inhibitors in Japan

By Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 7, 2006-11 ,pp. : 33-37

Springer Publishing Company

Access to resources Recommend Favorite

The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors

By Belani Chandra P.  

Cancer Investigation, Vol. 28, Iss. 4, 2010-04 ,pp. : 413-423

Informa Healthcare

Access to resources Recommend Favorite

Endothelial-cell apoptosis and tumour response to radiotherapy

By Abdulkarim B.   Deutsch E.  

Lancet Oncology, Vol. 5, Iss. 1, 2004-01 ,pp. : 9-9

Elsevier

Access to resources Recommend Favorite